Interface Biologics raises $5 million

Guest Contributor
December 23, 2008

Interface Biologics Inc has secured $5 million in syndicated financing as it moves into the clinical application and commercialization phase of its polymer products. The financing round for the Toronto-based biomaterials company was provided by Covington Capital, VG Partners and BDC Capital. Interface Biologics has established a strong intellectual property position for its nano-engineering biomedical polymers that cross the spectrum of medical devices. The firm also announced the appointment of Thomas Reeves as its new president and CEO. He comes to the company from medical devices company OccuLogix, where he was president and COO….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.